Download PDF
Thromb Haemost 2017; 117(02): 422-425
DOI: 10.1160/TH16-06-0451
Letters to the Editor
Schattauer GmbH

Antithrombin is not protective against renal ischaemia-reperfusion injury

Yasmine Bourti
1   INSERM UMR-S1176, Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
,
François Saller
1   INSERM UMR-S1176, Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
,
Elsa P. Bianchini
1   INSERM UMR-S1176, Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
,
Stéphane Pautus
1   INSERM UMR-S1176, Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
,
Jean-Paul Duong Van Huyen
2   APHP, Anatomie Pathologie, Hôpital Universitaire Necker-Enfants Malades, Paris, France
,
Anne-Lise Marie
3   CNRS UMR-8612, Univ. Paris-Sud, Université Paris-Saclay, Chatenay-Malabry, France
,
N. Thuy Tran
3   CNRS UMR-8612, Univ. Paris-Sud, Université Paris-Saclay, Chatenay-Malabry, France
,
Thierry Jo Molina
2   APHP, Anatomie Pathologie, Hôpital Universitaire Necker-Enfants Malades, Paris, France
,
Myriam Taverna
3   CNRS UMR-8612, Univ. Paris-Sud, Université Paris-Saclay, Chatenay-Malabry, France
,
Nicolas Lerolle
4   Angers University Hospital, Medical Intensive Care Unit, Angers, France
,
Delphine Borgel
1   INSERM UMR-S1176, Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
5   APHP, Laboratoire d’Hématologie, Hôpital Universitaire Necker-Enfants Malades, Paris, France
› Author Affiliations Financial support: This work was supported by a research grant from the Agence Nationale de la Recherche (no. ANR-2011-RPIB-018). Y. B. received funding from CORRDIM (Cardiovasculaire Obésité Rein Diabète – Domaine d’Intérêt Majeur). A.-L. M. received a grant for one year (2014–2015) from the Laboratoire français du Fractionnement et des Biotechnologies.
Further Information

Publication History

Received:15 June 2016

Accepted after major revision:06 October 2016

Publication Date:
01 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Souter PJ, Thomas S, Hubbard AR. et al. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001; 29: 134-139.
    CrossrefPubMedGoogle Scholar
  • 2 Dunzendorfer S, Kaneider N, Rabensteiner A. et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 2001; 97: 1079-1085.
    CrossrefPubMedGoogle Scholar
  • 3 Harada N, Okajima K, Uchiba M. et al. Antithrombin reduces ischemia/reperfusion-induced liver injury in rats by activation of cyclooxygenase-1. Thromb Haemost 2004; 92: 550-558.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Schoots IG, Levi M, van Vliet AK. et al. Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats. Crit Care Med 2004; 32: 1375-1383.
    CrossrefPubMedGoogle Scholar
  • 5 Wang J, Wang Y, Wang J. et al. Antithrombin is protective against myocardial ischemia and reperfusion injury. J Thromb Haemost 2013; 11: 1020-1028.
    CrossrefPubMedGoogle Scholar
  • 6 Minnema MC, Chang ACK, Jansen PM. et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95: 1117-1123.
    PubMedGoogle Scholar
  • 7 Dickneite G. A comparison of the pharmacokinetics of antithrombin derived from human plasma and from transgenic goats and the prevention of sepsis in an animal model. Biopharm Drug Dispos 2008; 29: 356-365.
    CrossrefPubMedGoogle Scholar
  • 8 Warren BL, Eid A, Singer P. et al. High-dose antithrombin iii in severe sepsis: A randomized controlled trial. J Am Med Assoc 2001; 286: 1869-1878.
    CrossrefPubMedGoogle Scholar
  • 9 Retractions. Mizutani A, Okajima K, Uchiba M, Noguchi TActivated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000; 95: 3781-3787and Mizutani A, Okajima K, Uchiba M, et al. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101: 3029-3036 Blood 2013; 122: 302.
    CrossrefPubMed
  • 10 Dong W, Wang H, Shahzad K. et al. Activated Protein C Ameliorates Renal Ischemia-Reperfusion Injury by Restricting Y-Box Binding Protein-1 Ubiquitination. J Am Soc Nephrol 2015; 26: 2789-2799.
    CrossrefPubMedGoogle Scholar
  • 11 Sabbisetti VS, Ito K, Wang C. et al. Novel assays for detection of urinary KIM-1 in mouse models of kidney injury. Toxicol Sci Off J Soc Toxicol 2013; 131: 13-25.
    CrossrefPubMedGoogle Scholar
  • 12 European Medicines Agency Product information - ATryn available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000587/WC500028260.pdf
    PubMed
  • 13 Compendium Suisse des Médicaments®. Information professionnelle - Kybernin® P available at: https://compendium.ch/mpro/mnr/21594/html/fr
    PubMed
  • 14 Agence Nationale de Sécurité du Médicament et des Produits de Santé. Résumé des caractéristiques du produit - Aclotine available at: http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0137874.htm#Rcp_6_1_ListeExcipients
    PubMed
  • 15 Zhong X, Li X, Qian L. et al. Glycine attenuates myocardial ischemia-reperfusion injury by inhibiting myocardial apoptosis in rats. J Biomed Res 2012; 26: 346-354.
    CrossrefPubMedGoogle Scholar
  • 16 Lu Y, Zhang J, Ma B. et al. Glycine attenuates cerebral ischemia/reperfusion injury by inhibiting neuronal apoptosis in mice. Neurochem Int 2012; 61: 649-658.
    CrossrefPubMedGoogle Scholar
  • 17 Petrat F, Drowatzky J, Boengler K. et al. Protection from glycine at low doses in ischemia-reperfusion injury of the rat small intestine. Eur Surg Res 2011; 46: 180-187.
    CrossrefPubMedGoogle Scholar
  • 18 Duru S, Koca U, Oztekin S. et al. Antithrombin III pretreatment reduces neutrophil recruitment into the lung and skeletal muscle tissues in the rat model of bilateral lower limb ischemia and reperfusion: a pilot study. Acta Anaesthesiol Scand 2005; 49: 1142-1148.
    CrossrefPubMedGoogle Scholar
  • 19 Zambas NA, Karkos CD, Kambaroudis AG. et al. Protective effect of antithrombin III against lung and myocardial injury in lower-limb ischemia-reperfusion syndrome. Ann Vasc Surg 2012; 26: 566-570.
    CrossrefPubMedGoogle Scholar
  • 20 Bianchini EP, Fazavana J, Picard V. et al. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives. Blood 2011; 117: 2054-2060.
    CrossrefPubMedGoogle Scholar
  • 21 Bock F, Shahzad K, Wang H. et al. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc Natl Acad Sci USA 2013; 110: 648-653.
    CrossrefPubMedGoogle Scholar
  • 22 Chang WS, Harper PL. Commercial antithrombin concentrate contains inactive L-forms of antithrombin. Thromb Haemost 1997; 77: 323-328.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Zhou A, Huntington JA, Carrell RW. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood 1999; 94: 3388-3396.
    CrossrefPubMedGoogle Scholar
  • 24 Heger A, Grunert T, Schulz P. et al. Separation of active and inactive forms of human antithrombin by heparin affinity chromatography. Thromb Res 2002; 106: 157-164.
    CrossrefPubMedGoogle Scholar
  • 25 Marie A-L, Tran NT, Saller F. et al. A capillary zone electrophoresis method to detect conformers and dimers of antithrombin in therapeutic preparations.Electrophoresis 2016 Mar 16. doi: 10.1002/elps.201500456.
    PubMedGoogle Scholar